Activation of the alternative NFκB pathway improves disease symptoms in a model of Sjogren's syndrome

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Gilboa Geffen, Adi ^a   Wolf, Yochai ^a   Hanin, Geula ^a   Melamed Book, Naomi ^a   Pick, Marjorie ^a   Bennett, Estelle R ^a   Greenberg, David S ^a   Lester, Susan ^b   Rischmueller, Maureen ^b   Soreq, Hermona ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b QUEEN ELIZABETH HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINESTERASE; ALPHA INTERFERON; APTAMER; BIOLOGICAL MARKER; BL 7040; CASPASE 3; CPG OLIGODEOXYNUCLEOTIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOLEAMINE 2,3 DIOXYGENASE; MITOGEN ACTIVATED PROTEIN KINASE 14; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; AUTACOID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN ANTIBODY COMPLEX; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; AUTOIMMUNITY; CELL INFILTRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ASSOCIATION; DOWN REGULATION; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOCYTOCHEMISTRY; INFLAMMATION; MOUSE; NEUROTRANSMISSION; NONHUMAN; PHENOTYPE; PLASMACYTOID DENDRITIC CELL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SALIVARY GLAND; SALIVATION; SIGNAL TRANSDUCTION; SJOEGREN SYNDROME; ANIMAL; CELL LINE; DISEASE MODEL; DRUG POTENTIATION; METABOLISM; MONONUCLEAR CELL; PATHOLOGY; PATHOPHYSIOLOGY; SALIVA; SECRETION;

ANIMALS; BIOLOGICAL MARKERS; CELL LINE; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION MEDIATORS; LEUKOCYTES, MONONUCLEAR; MICE; NF-KAPPA B; SALIVA; SALIVARY GLANDS; SIGNAL TRANSDUCTION; SJOGREN'S SYNDROME; TOLL-LIKE RECEPTOR 9;

EID: 83055198367     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028727     Document Type: Article

References (48)

1. Ramos-Casals M, Font J, (2005) Primary Sjogren's syndrome: current and emergent aetiopathogenic concepts. Rheumatology (Oxford) 44: 1354-1367.
2. Fox RI, (2005) Sjogren's syndrome. Lancet 366: 321-331.
3. Waterman SA, Gordon TP, Rischmueller M, (2000) Inhibitory effects of muscarinic receptor autoantibodies on parasympathetic neurotransmission in Sjogren's syndrome. Arthritis Rheum 43: 1647-1654.
4. Routsias JG, Tzioufas AG, (2010) Autoimmune response and target autoantigens in Sjogren's syndrome. Eur J Clin Invest 40: 1026-1036.
5. Krieg AM, (2006) Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 5: 471-484.
6. Ehlers M, Ravetch JV, (2007) Opposing effects of Toll-like receptor stimulation induce autoimmunity or tolerance. Trends Immunol 28: 74-79.
7. Vallabhapurapu S, Karin M, (2009) Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol 27: 693-733.
8. Latz E, Verma A, Visintin A, Gong M, Sirois CM, et al. (2007) Ligand-induced conformational changes allosterically activate Toll-like receptor 9. Nat Immunol 8: 772-779.
9. Nordmark G, Alm GV, Ronnblom L, (2006) Mechanisms of Disease: primary Sjogren's syndrome and the type I interferon system. Nat Clin Pract Rheumatol 2: 262-269.
10. Puccetti P, Grohmann U, (2007) IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-kappaB activation. Nat Rev Immunol 7: 817-823.
11. Tang Q, Bluestone JA, (2006) Regulatory T-cell physiology and application to treat autoimmunity. Immunol Rev 212: 217-237.
12. Dawson LJ, Stanbury J, Venn N, Hasdimir B, Rogers SN, et al. (2006) Antimuscarinic antibodies in primary Sjogren's syndrome reversibly inhibit the mechanism of fluid secretion by human submandibular salivary acinar cells. Arthritis Rheum 54: 1165-1173.
13. Garrett JR, Kidd A, (1993) The innervation of salivary glands as revealed by morphological methods. Microsc Res Tech 26: 75-91.
14. Dawson LJ, Field EA, Harmer AR, Smith PM, (2001) Acetylcholine-evoked calcium mobilization and ion channel activation in human labial gland acinar cells from patients with primary Sjogren's syndrome. Clin Exp Immunol 124: 480-485.
15. Wang H, Yu M, Ochani M, Amella CA, Tanovic M, et al. (2003) Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 421: 384-388.
16. Kawashima K, Fujii T, (2003) The lymphocytic cholinergic system and its contribution to the regulation of immune activity. Life Sci 74: 675-696.
17. Tracey KJ, (2009) Reflex control of immunity. Nat Rev Immunol 9: 418-428.
18. Gilliet M, Cao W, Liu YJ, (2008) Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol 8: 594-606.
19. Argov Z, McKee D, Agus S, Brawer S, Shlomowitz N, et al. (2007) Treatment of human myasthenia gravis with oral antisense suppression of acetylcholinesterase. Neurology 69: 699-700.
20. Dawson LJ, Caulfield VL, Stanbury JB, Field AE, Christmas SE, et al. (2005) Hydroxychloroquine therapy in patients with primary Sjogren's syndrome may improve salivary gland hypofunction by inhibition of glandular cholinesterase. Rheumatology (Oxford) 44: 449-455.
21. Anderson MS, Bluestone JA, (2005) The NOD mouse: a model of immune dysregulation. Annu Rev Immunol 23: 447-485.
22. Evron T, Moyal-Segal LB, Lamm N, Geffen A, Soreq H, (2005) RNA-targeted suppression of stress-induced allostasis in primate spinal cord neurons. Neurodegener Dis 2: 16-27.
23. West AP, Brodsky IE, Rahner C, Woo DK, Erdjument-Bromage H, et al. (2011) TLR signalling augments macrophage bactericidal activity through mitochondrial ROS. Nature 472: 476-480.
24. Lenert P, (2005) Inhibitory oligodeoxynucleotides- therapeutic promise for systemic autoimmune diseases? Clin Exp Immunol 140: 1-10.
25. Soyfoo MS, Steinfeld S, Delporte C, (2007) Usefulness of mouse models to study the pathogenesis of Sjogren's syndrome. Oral Dis 13: 366-375.
26. Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, et al. (2006) The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol 176: 6752-6761.
27. Tishler M, Yaron I, Shirazi I, Yaron M, (1999) Hydroxychloroquine treatment for primary Sjogren's syndrome: its effect on salivary and serum inflammatory markers. Ann Rheum Dis 58: 253-256.
28. Fallarino F, Volpi C, Zelante T, Vacca C, Calvitti M, et al. (2009) IDO mediates TLR9-driven protection from experimental autoimmune diabetes. J Immunol 183: 6303-6312.
29. Dejardin E, (2006) The alternative NF-kappaB pathway from biochemistry to biology: pitfalls and promises for future drug development. Biochem Pharmacol 72: 1161-1179.
30. Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, et al. (1979) Immune interferon in the circulation of patients with autoimmune disease. The New England journal of medicine 301: 5-8.
31. Azuma M, Motegi K, Aota K, Hayashi Y, Sato M, (1997) Role of cytokines in the destruction of acinar structure in Sjogren's syndrome salivary glands. Lab Invest 77: 269-280.
32. Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, et al. (2006) Tryptophan catabolism generates autoimmune-preventive regulatory T cells. Transpl Immunol 17: 58-60.
33. Soreq H, Seidman S, (2001) Acetylcholinesterase-new roles for an old actor. Nat Rev Neurosci 2: 294-302.
34. Tang Q, Bluestone JA, (2006) Plasmacytoid DCs and T(reg) cells: casual acquaintance or monogamous relationship? Nat Immunol 7: 551-553.
35. Ben-Zvi I, Kivity S, Langevitz P, Shoenfeld Y, (2011) Hydroxychloroquine: From Malaria to Autoimmunity. Clinical reviews in allergy & immunology.
36. Sun S, Rao NL, Venable J, Thurmond R, Karlsson L, (2007) TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm Allergy Drug Targets 6: 223-235.
37. Shaked I, Meerson A, Wolf Y, Avni R, Greenberg D, et al. (2009) MicroRNA-132 potentiates cholinergic anti-inflammatory signaling by targeting acetylcholinesterase. Immunity 31: 965-973.
38. Sklan EH, Lowenthal A, Korner M, Ritov Y, Landers DM, et al. (2004) Acetylcholinesterase/paraoxonase genotype and expression predict anxiety scores in Health, Risk Factors, Exercise Training, and Genetics study. Proc Natl Acad Sci U S A 101: 5512-5517.
39. Ben Assayag E, Shenhar-Tsarfaty S, Ofek K, Soreq L, Bova I, et al. (2010) Serum cholinesterase activities distinguish between stroke patients and controls and predict 12 month mortality. MolMed in press.
40. Bonizzi G, Karin M, (2004) The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 25: 280-288.
41. Hoshino K, Sugiyama T, Matsumoto M, Tanaka T, Saito M, et al. (2006) IkappaB kinase-alpha is critical for interferon-alpha production induced by Toll-like receptors 7 and 9. Nature 440: 949-953.
42. Lu LF, Gondek DC, Scott ZA, Noelle RJ, (2005) NF kappa B-inducing kinase deficiency results in the development of a subset of regulatory T cells, which shows a hyperproliferative activity upon glucocorticoid-induced TNF receptor family-related gene stimulation. J Immunol 175: 1651-1657.
43. Lawrence T, Bebien M, Liu GY, Nizet V, Karin M, (2005) IKKalpha limits macrophage NF-kappaB activation and contributes to the resolution of inflammation. Nature 434: 1138-1143.
44. Kinoshita D, Hirota F, Kaisho T, Kasai M, Izumi K, et al. (2006) Essential role of IkappaB kinase alpha in thymic organogenesis required for the establishment of self-tolerance. J Immunol 176: 3995-4002.
45. Beinke S, Ley SC, (2004) Functions of NF-kappaB1 and NF-kappaB2 in immune cell biology. Biochem J 382: 393-409.
46. Berson A, Knobloch M, Hanan M, Diamant S, Sharoni M, et al. (2008) Changes in readthrough acetylcholinesterase expression modulate amyloid-beta pathology. Brain 131: 109-119.
47. Soreq L, Israel Z, Bergman H, Soreq H, (2008) Advanced microarray analysis highlights modified neuro-immune signaling in nucleated blood cells from Parkinson's disease patients. J Neuroimmunol 201-202: 227-236.
48. Gilboa-Geffen A, Lacoste PP, Soreq L, Cizeron-Clairac G, Le Panse R, et al. (2007) The thymic theme of acetylcholinesterase splice variants in myasthenia gravis. Blood 109: 4383-4391.